Drug Profile
Glucosylceramide
Alternative Names: GCLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Enzo Biochem
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Crohn's disease
Most Recent Events
- 30 Sep 2009 Discontinued - Preclinical for Crohn's disease in Israel (unspecified route)
- 04 Nov 2004 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
- 09 Jun 2004 Data presented at the Digestive Disease Week-2004 (DDW-2004) have been added to the Inflammatory Bowel Disorders pharmacodynamics section